ATE475673T1 - Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung - Google Patents

Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung

Info

Publication number
ATE475673T1
ATE475673T1 AT04749427T AT04749427T ATE475673T1 AT E475673 T1 ATE475673 T1 AT E475673T1 AT 04749427 T AT04749427 T AT 04749427T AT 04749427 T AT04749427 T AT 04749427T AT E475673 T1 ATE475673 T1 AT E475673T1
Authority
AT
Austria
Prior art keywords
antibodies
binding partners
methods
inflammation
antagonizing
Prior art date
Application number
AT04749427T
Other languages
English (en)
Inventor
Wenfeng Xu
Wayne Kindsvogel
Yasmin Chandrasekher
Stacey Dillon
Joyce Lehner
Anthony Siadak
Pallavur Sivakumar
Margaret Moore
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33101289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE475673(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE475673T1 publication Critical patent/ATE475673T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04749427T 2003-03-24 2004-03-24 Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung ATE475673T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45748103P 2003-03-24 2003-03-24
US52329503P 2003-11-17 2003-11-17
PCT/US2004/008956 WO2004085476A2 (en) 2003-03-24 2004-03-24 Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Publications (1)

Publication Number Publication Date
ATE475673T1 true ATE475673T1 (de) 2010-08-15

Family

ID=33101289

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749427T ATE475673T1 (de) 2003-03-24 2004-03-24 Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung

Country Status (16)

Country Link
US (6) US20060134756A1 (de)
EP (2) EP1606317B1 (de)
JP (2) JP2007525437A (de)
KR (3) KR20050116390A (de)
CN (2) CN103864934A (de)
AT (1) ATE475673T1 (de)
AU (2) AU2004223837C1 (de)
BR (2) BRPI0408683A (de)
CA (2) CA2519057A1 (de)
DE (1) DE602004028347D1 (de)
DK (1) DK1606317T3 (de)
EA (2) EA009124B1 (de)
ES (1) ES2347657T3 (de)
MX (2) MXPA05010136A (de)
NO (1) NO20054892L (de)
WO (2) WO2004085475A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
EP1337636B1 (de) * 2000-08-08 2006-10-18 ZymoGenetics, Inc. Lösliche zcyctor 11 cytokinrezeptoren
DE60141546D1 (de) 2000-09-15 2010-04-22 Zymogenetics Inc Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
EP1977760A3 (de) 2001-12-17 2009-11-04 ZymoGenetics, Inc. Verfahren zur Behandlung von Infektionen durch Humanes Papilloma Virus (HPV)
US20060134756A1 (en) 2003-03-24 2006-06-22 Wenfeng Xu Anti-IL-20 antibodies and binding partners and methods of using in inflammation
CA2542546A1 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
US7713737B2 (en) * 2004-10-04 2010-05-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
JP4898691B2 (ja) 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
WO2006086396A2 (en) * 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
ES2547689T3 (es) * 2005-12-02 2015-10-08 Genentech, Inc. Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R
EP1966246A4 (de) * 2005-12-05 2010-01-06 Trinity Biosystems Inc Verfahren und zusammensetzungen zur nadellosen verabreichung von antikörpern
US20090148401A1 (en) * 2005-12-05 2009-06-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
EP1969008A4 (de) * 2005-12-22 2009-08-12 Dhy & Co Ltd Antikörper gegen interleukin-22-bindendes protein und deren anwendungen bei der behandlung von stoffwechselstörungen
US20090305978A1 (en) * 2006-03-16 2009-12-10 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
TWI419703B (zh) 2006-06-08 2013-12-21 Chugai Pharmaceutical Co Ltd The use of anti-NR10 antibodies with neutralizing activity against human NR10 and Cynomolgus monkey NR10
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
CA2978687C (en) 2007-09-26 2020-02-18 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
KR101595134B1 (ko) 2007-12-05 2016-02-17 추가이 세이야쿠 가부시키가이샤 소양증 치료제
ES2585480T3 (es) 2007-12-05 2016-10-06 Chugai Seiyaku Kabushiki Kaisha Anticuerpo anti-NR10 y uso del mismo
NZ588507A (en) 2008-04-11 2012-11-30 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR20110039218A (ko) 2008-06-30 2011-04-15 노보 노르디스크 에이/에스 항－인간 인터루킨－２０ 항체
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2409990A4 (de) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd Variante einer konstanten antikörperregion
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
CN107973851A (zh) 2010-11-30 2018-05-01 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
DK2686347T3 (en) 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
WO2013020904A1 (en) * 2011-08-05 2013-02-14 Universite D'aix-Marseille Fibrosis susceptibility il22ra2 gene and uses thereof
US8597647B1 (en) 2012-05-22 2013-12-03 National Cheng Kung University Humanized anti-IL-20 antibody and uses thereof
WO2014006230A1 (en) * 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
JP6391574B2 (ja) * 2012-08-31 2018-09-26 アルゲン−エックス ビーブイビーエー 種間標的内交差反応性を有する抗体分子を産生する方法
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
RU2683020C2 (ru) * 2014-11-11 2019-03-26 Петр Иванович Никитин Субстанция и способ для модуляции активности агента в организме
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
EP3464357A1 (de) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von bakteriellen lungeninfektionen
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
US20220177912A1 (en) * 2019-04-12 2022-06-09 The Methodist Hospital Therapeutic particles that enable antigen presenting cells to attack cancer cells
EP3984553A4 (de) * 2019-06-12 2023-07-19 Acurasysbio Co., Ltd. Zusammensetzung zur prävention oder behandlung von krebs
KR20220098046A (ko) 2019-11-20 2022-07-08 추가이 세이야쿠 가부시키가이샤 항체 함유 제제

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
EP0154316B1 (de) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
NZ212437A (en) * 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) * 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
EP0742830B1 (de) 1994-02-01 2001-07-18 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
JP3713074B2 (ja) * 1995-08-30 2005-11-02 栄研化学株式会社 血清アミロイドａを認識するモノクローナル抗体
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU8571198A (en) 1997-07-16 1999-02-10 Human Genome Sciences, Inc. Interleukin-20
US6486301B1 (en) * 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
KR100236609B1 (ko) * 1997-08-01 2000-02-01 박호군 클로로하이드로실란 유도체 및 이의 제조방법
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
CA2298439A1 (en) 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
EA005581B1 (ru) * 1997-11-26 2005-04-28 Займодженетикс, Инк. ПОЛИПЕПТИДЫ ЦИТОКИНА Zcyto10 ЧЕЛОВЕКА И МЫШИ, КОДИРУЮЩИЕ ИХ ПОЛИНУКЛЕОТИДЫ И АНТИТЕЛА К УКАЗАННЫМ ПОЛИПЕПТИДАМ
ES2226335T3 (es) 1998-01-23 2005-03-16 Immunex Corporation Receooctires de uk.18.
WO1999046379A2 (en) 1998-03-09 1999-09-16 Schering Corporation Human receptor proteins; related reagents and methods
DK1490386T3 (da) 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU5203199A (en) 1998-05-26 1999-12-13 Procter & Gamble Company, The Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
WO2000024758A1 (en) 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
EP1141008A1 (de) 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Cytokinin klasse ii rezeptor-ähnliche proteine und für diese kodierende nukleinsäuren
PT1177312E (pt) 1999-04-28 2008-01-22 Genetics Inst Llc Proteínas gil-19/ae289 humanas e polinucleótidos codificadores das mesmas
CA2373231A1 (en) 1999-05-19 2000-11-23 Incyte Genomics, Inc. Extracellular signaling molecules
WO2000073457A1 (en) 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
EP1208195A2 (de) 1999-06-15 2002-05-29 Genentech Inc. Ausgeschiedene und transmembran-polypeptide und dafür kodierende nukleinsäure
JP4737903B2 (ja) 1999-07-07 2011-08-03 ザイモジェネティクス， インコーポレイテッド ヒトサイトカイン受容体
CA2380355A1 (en) 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA02005058A (es) 1999-11-18 2002-11-07 Schering Corp Proteinas de mamiferos receptoras, reactivos y metodos relacionados.
EP1234035B1 (de) 1999-12-03 2010-02-24 ZymoGenetics, Inc. Menschliches zytokinrezeptor
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
AU2292601A (en) 1999-12-23 2001-07-03 Zymogenetics Inc. Novel cytokine zcyto18
ATE407950T1 (de) 1999-12-23 2008-09-15 Zymogenetics Inc Löslicher interleukin-20 rezeptor
EP2295078A3 (de) * 1999-12-23 2011-03-23 ZymoGenetics, L.L.C. Verfahren zur Behandlung von Entzündungen
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
JP2002015498A (ja) * 2000-06-29 2002-01-18 Fujitsu Ltd センス電流の設定方法
EP1337636B1 (de) * 2000-08-08 2006-10-18 ZymoGenetics, Inc. Lösliche zcyctor 11 cytokinrezeptoren
WO2002020569A2 (en) 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
DE60141546D1 (de) 2000-09-15 2010-04-22 Zymogenetics Inc Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US20030022827A1 (en) 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
AU2002249948B2 (en) 2001-01-12 2007-08-23 Genetics Institute, Llc Type 2 cytokine receptor and nucleic acids encoding same
WO2002058724A2 (en) 2001-01-26 2002-08-01 Eli Lilly And Company Use of lp82 to treat body weight disorders
MXPA03007413A (es) 2001-02-23 2003-11-18 Inst Genetics Llc Composicion y metodo para tratar enfermedades inflamatorias.
CN1503677A (zh) * 2001-02-28 2004-06-09 用lp82治疗造血障碍
US6875845B2 (en) 2001-03-02 2005-04-05 Zymogenetics, Inc. Mouse cytokine receptor
JP4009535B2 (ja) * 2001-03-09 2007-11-14 ザイモジェネティクス，インコーポレイティド 可溶性ヘテロダイマーサイトカイン受容体
JP2005503765A (ja) 2001-03-27 2005-02-10 ザイモジェネティクス，インコーポレイティド ヒトサイトカイン受容体
WO2002092771A2 (en) * 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
EP1439850A4 (de) 2001-10-22 2006-05-03 Lilly Co Eli Lösliche proteine, die zytokin-signalübertragungspfade hemmen
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
EP1977760A3 (de) 2001-12-17 2009-11-04 ZymoGenetics, Inc. Verfahren zur Behandlung von Infektionen durch Humanes Papilloma Virus (HPV)
US20040236075A1 (en) 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
US20060134756A1 (en) 2003-03-24 2006-06-22 Wenfeng Xu Anti-IL-20 antibodies and binding partners and methods of using in inflammation
CN1798768B (zh) * 2003-03-24 2013-05-08 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣及其应用
CA2542546A1 (en) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
JP4898691B2 (ja) * 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法

Also Published As

Publication number Publication date
WO2004085476A2 (en) 2004-10-07
US20100111948A1 (en) 2010-05-06
EP1606316A2 (de) 2005-12-21
AU2004223837C1 (en) 2012-03-15
EP1606317A2 (de) 2005-12-21
WO2004085475A3 (en) 2005-07-14
US20060134756A1 (en) 2006-06-22
US20090074661A1 (en) 2009-03-19
CA2519089C (en) 2014-12-23
DE602004028347D1 (de) 2010-09-09
BRPI0408705A (pt) 2006-03-07
DK1606317T3 (da) 2010-10-25
US20120207761A1 (en) 2012-08-16
AU2004223836A1 (en) 2004-10-07
NO20054892L (no) 2005-12-23
AU2004223836A2 (en) 2004-10-07
MXPA05010134A (es) 2005-11-16
EP1606317B1 (de) 2010-07-28
WO2004085475A2 (en) 2004-10-07
US8163286B2 (en) 2012-04-24
EA009124B1 (ru) 2007-10-26
US20040209330A1 (en) 2004-10-21
AU2004223837A1 (en) 2004-10-07
AU2004223837B2 (en) 2011-04-21
AU2004223837A2 (en) 2004-10-07
EA200501505A1 (ru) 2006-06-30
MXPA05010136A (es) 2005-11-16
EA200501506A1 (ru) 2006-06-30
KR20050116390A (ko) 2005-12-12
EA009026B1 (ru) 2007-10-26
CA2519057A1 (en) 2004-10-07
KR20110091598A (ko) 2011-08-11
JP2007525438A (ja) 2007-09-06
CN102690350A (zh) 2012-09-26
CN103864934A (zh) 2014-06-18
KR20050116392A (ko) 2005-12-12
JP2007525437A (ja) 2007-09-06
CA2519089A1 (en) 2004-10-07
ES2347657T3 (es) 2010-11-03
NO20054892D0 (no) 2005-10-21
BRPI0408683A (pt) 2006-03-28
US20080233115A1 (en) 2008-09-25
WO2004085476A3 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
ATE475673T1 (de) Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
IL182503A0 (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
MXPA06014465A (es) Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
WO2005052001A3 (en) Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
EA200800956A1 (ru) Антагонисты il-17a и il-17f и способы их использования
WO2007106769A3 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
DE602007006429D1 (de) Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
NO20044658L (no) Anvendelse av osteoprotegerin til behandling og/eller forhindring av fibrotiske sykdommer
MX2007004597A (es) Zcytor21 soluble, anticuerpos anti-zcytor21 y moleculas de enlace y metodos de uso en inflamacion.
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
WO2005046714A3 (en) Cytokine antagonist molecules
DK1196188T3 (da) VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение
ATE319744T1 (de) Antikörper zur stimulierung der produktion von il-1ra

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1606317

Country of ref document: EP